Fidelity SPDR Advertisement
Home > Boards > Free Zone > User's Groups > Mohacsy's Safe Portfolio Member Forum

Orphan Drug Status doesn't assure FDA approval of

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
n4807g Member Profile
Member Level 
Followed By 30
Posts 26,962
Boards Moderated 0
Alias Born 07/08/03
160x600 placeholder
Germany's Merck To Buy Sigma-aldrich For $17 Billion
German pharmaceutical company Merck said it would acquire U.S. firm Sigma-Aldrich for $17 billion, paying $140 a share in cash, to strengthen its position in the life science industry.
More Top Equities Stories Of The Day
New Level of Smartphone Encryption Alarms Law Enforcement
German Firms Go on U.S. Buying Spree
Germany's Merck to Buy Sigma-Aldrich for $17 Billion--3rd Update
Investors Bet on Asia Despite U.S. Rate Threat
This Man's Job: Make Bill Gates Richer
U.S. Hot Stocks: Hot Stocks to Watch
U.S. Hog Futures Fall Sharply on Supply Concerns, Cattle Decline
U.S. Steel Canada to Seek Creditor Protection
n4807g Member Level  Monday, 04/23/12 12:16:00 PM
Re: FullBoogie post# 60301
Post # of 68198 
Orphan Drug Status doesn't assure FDA approval of the compound being evaluated, it confers certain marketing advantages and tax credits should the drug be approved.

Like most small biotechs CYTR will succeed or fail on the technology they employ. In CYTR's case the delivery system. The near term future of INNO-206 will be clear when they report interim findings of their ongoing 2b trial.

Like all biotechs this is a speculative investment, but I've watched many companies with similar strategies do well. The preliminary data look promising (no guarantee) but as I said in my previous post Abraxane uses Albumin as the entry vehicle in tumors and CYTR uses the same concept.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist